StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Axsome Therapeutics's total debt was $187.96M at Jun 30, 2026. For fiscal 2025 it was $187.75M, up 3.9% from the year before. The highest annual figure on record is $187.75M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$187.75M+3.9%
FY2024Dec 31, 2024$180.71M+1.5%
FY2023Dec 31, 2023$178.07M+88.9%
FY2022Dec 31, 2022$94.26M+92.0%
FY2021Dec 31, 2021$49.09M+1.6%
FY2020Dec 31, 2020$48.32M+142.4%
FY2019Dec 31, 2019$19.93M+188.5%
FY2018Dec 31, 2018$6.91M-30.4%
FY2017Dec 31, 2017$9.93M+2.0%
FY2016Dec 31, 2016$9.74M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$187.96M+0.2%
Q1 FY2026Mar 31, 2026$187.85M+3.6%
Q4 FY2025Dec 31, 2025$187.75M+3.9%
Q3 FY2025Sep 30, 2025$187.64M+4.2%
Q2 FY2025Jun 30, 2025$187.54M+4.6%
Q1 FY2025Mar 31, 2025$181.38M+1.5%
Q4 FY2024Dec 31, 2024$180.71M+1.5%
Q3 FY2024Sep 30, 2024$180.00M+1.4%
Q2 FY2024Jun 30, 2024$179.33M+1.4%
Q1 FY2024Mar 31, 2024$178.69M+21.1%
Q4 FY2023Dec 31, 2023$178.07M+88.9%
Q3 FY2023Sep 30, 2023$177.45M+88.9%
Q2 FY2023Jun 30, 2023$176.82M+89.2%
Q1 FY2023Mar 31, 2023$147.62M+199.3%
Q4 FY2022Dec 31, 2022$94.26M+92.0%
Q3 FY2022Sep 30, 2022$93.91M+91.0%
Q2 FY2022Jun 30, 2022$93.46M+91.2%
Q1 FY2022Mar 31, 2022$49.31M+1.5%
Q4 FY2021Dec 31, 2021$49.09M+1.6%
Q3 FY2021Sep 30, 2021$49.17M+2.4%
Q2 FY2021Jun 30, 2021$48.88M+140.9%
Q1 FY2021Mar 31, 2021$48.60M+141.6%
Q4 FY2020Dec 31, 2020$48.32M+142.4%
Q3 FY2020Sep 30, 2020$48.03M+143.1%
Q2 FY2020Jun 30, 2020$20.29M+3.6%
Q1 FY2020Mar 31, 2020$20.11M+3.9%
Q4 FY2019Dec 31, 2019$19.93M+188.5%
Q3 FY2019Sep 30, 2019$19.76M+155.7%
Q2 FY2019Jun 30, 2019$19.58M+131.1%
Q1 FY2019Mar 31, 2019$19.35M+110.2%
Q4 FY2018Dec 31, 2018$6.91M-30.4%
Q3 FY2018Sep 30, 2018$7.73M-23.4%
Q2 FY2018Jun 30, 2018$8.47M-15.1%
Q1 FY2018Mar 31, 2018$9.21M-6.6%
Q4 FY2017Dec 31, 2017$9.93M+2.0%
Q3 FY2017Sep 30, 2017$10.09M–
Q2 FY2017Jun 30, 2017$9.97M–
Q1 FY2017Mar 31, 2017$9.86M–
Q4 FY2016Dec 31, 2016$9.74M–

More Axsome Therapeutics figures

See a number that looks wrong?